Want to see DNTH full AI Analyst Report?
Top Page
Dianthus Therapeutics
(NASDAQ:DNTH)
Select Model
Select Model
Rating:58Neutral
Price Target:
$115.00
▲(10.72% Upside)
Action:Reiterated
Date:08/05/26
The score is held back primarily by weak financial performance—ongoing losses and increasing cash burn—despite a strong, low-debt balance sheet. Technically, the stock shows solid upward momentum (trading above key moving averages with a positive MACD), and recent clinical progress is a meaningful positive, but traditional valuation remains unattractive due to unprofitability and no dividend.
Positive Factors
Low Leverage / Strong Balance Sheet
Extremely low debt and expanding equity/assets reduce financial risk and give management runway to fund clinical programs without immediate refinancing. This balance-sheet strength supports multi-year R&D plans and strategic flexibility across the next several quarters.
Negative Factors
Rising Cash Burn
Materially increasing negative operating cash flow shows growing cash consumption as trials advance. Even with strong cash today, continued higher burn elevates financing risk and could force program prioritization or dilution if milestones take longer or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Extremely low debt and expanding equity/assets reduce financial risk and give management runway to fund clinical programs without immediate refinancing. This balance-sheet strength supports multi-year R&D plans and strategic flexibility across the next several quarters.
Read all positive factors
Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.42B
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-60.77%
EPS Growth-27.57%
CountryUS
Employees92
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding55,934,380
10 Day Avg. Volume895,608
30 Day Avg. Volume1,227,272
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$140.64Price Target Upside35.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$1.78M
Dianthus Therapeutics Business Overview & Revenue Model
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with exten...
How the Company Makes Money
null...
Dianthus Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.90M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| Gross Profit | 1.83M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| EBITDA | -29.51M | -161.91M | -84.56M | -43.20M | -28.33M | -11.09M |
| Net Income | -29.91M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M |
Balance Sheet | ||||||
| Total Assets | 1.21B | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M |
| Cash, Cash Equivalents and Short-Term Investments | 886.81M | 404.30M | 275.24M | 173.72M | 75.49M | 176.93M |
| Total Debt | 1.29M | 1.39M | 1.49M | 585.00K | 788.00K | 0.00 |
| Total Liabilities | 41.25M | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M |
| Stockholders Equity | 1.17B | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M |
Cash Flow | ||||||
| Free Cash Flow | -155.71M | -129.27M | -78.28M | -36.97M | -29.21M | -60.80M |
| Operating Cash Flow | -155.38M | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M |
| Investing Cash Flow | -776.56M | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M |
| Financing Cash Flow | 1.03B | 280.13M | 255.62M | 133.57M | 96.68M | 89.60M |
Dianthus Therapeutics Technical Analysis
Positive
103.87
Price Trends
98.53
Positive
92.97
Positive
71.25
Positive
Market Momentum
4.27
Negative
61.13
Neutral
87.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 103.87 is below the 20-day moving average (MA) of 108.88, above the 50-day MA of 98.53, and above the 200-day MA of 71.25, indicating a bullish trend. The MACD of 4.27 indicates Negative momentum. The RSI at 61.13 is Neutral, neither overbought nor oversold. The STOCH value of 87.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.
Dianthus Therapeutics Risk Analysis
Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dianthus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.78B | -23.81 | -39.01% | ― | ― | -18.88% | |
61 Neutral | $2.39B | -24.49 | -52.92% | ― | ― | 42.67% | |
58 Neutral | $6.42B | -883.54 | -3.51% | ― | -60.77% | -27.57% | |
56 Neutral | $994.08M | -10.20 | -10.79% | ― | 5366.97% | 8.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.18B | -3.12 | -1328.94% | ― | ― | 39.33% | |
47 Neutral | $1.01B | -17.99 | -36.00% | ― | 16.77% | 4.11% |
* Healthcare Sector Average
DNTH
Dianthus Therapeutics
115.54
92.84
408.99%
ARDX
Ardelyx
3.92
-1.94
-33.11%
EWTX
Edgewise Therapeutics
44.11
30.31
219.64%
JANX
Janux Therapeutics Inc
16.96
-7.74
-31.34%
AMLX
Amylyx Pharmaceuticals Inc
35.11
27.29
348.98%
BHVN
Biohaven Ltd.
13.57
-1.68
-11.02%
Dianthus Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Dianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
Positive
Jun 12, 2026
On June 11, 2026, Dianthus Therapeutics reported interim responder analysis data from the first 40 patients completing Part A of its Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, showing a 75% respon...
Executive/Board ChangesShareholder Meetings
Dianthus Therapeutics Stockholders Reaffirm Board and Governance Structure
Positive
May 22, 2026
On May 21, 2026, Dianthus Therapeutics held its Annual Meeting of Stockholders, where investors elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting, reaffirming the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.